These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 26798584)

  • 1. Immunotherapy meets targeted therapy: will this team end the war against cancer?
    Morales-Espinosa D; García-Román S; Teixidó C; Karachaliou N; Rosell R
    Transl Lung Cancer Res; 2015 Dec; 4(6):752-5. PubMed ID: 26798584
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy in Bladder Cancer.
    Vasekar M; Degraff D; Joshi M
    Curr Mol Pharmacol; 2016; 9(3):242-251. PubMed ID: 26177642
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects.
    Jia H; Truica CI; Wang B; Wang Y; Ren X; Harvey HA; Song J; Yang JM
    Drug Resist Updat; 2017 May; 32():1-15. PubMed ID: 29145974
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular and Genomic Determinants of Response to Immune Checkpoint Inhibition in Cancer.
    Jenkins RW; Thummalapalli R; Carter J; Cañadas I; Barbie DA
    Annu Rev Med; 2018 Jan; 69():333-347. PubMed ID: 29099676
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Personalized chemotherapy of lung cancer: What the radiologist should know.
    Ferretti GR; Reymond E; Delouche A; Sakhri L; Jankowski A; Moro-Sibilot D; Lantuejoul S; Toffart AC
    Diagn Interv Imaging; 2016 Mar; 97(3):287-96. PubMed ID: 26857787
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beware the Medical-Industrial Complex.
    Stevens CW; Glatstein E
    Oncologist; 1996; 1(4):IV-V. PubMed ID: 10388005
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Harnessing the immune system for cancer therapy.
    Smith EL; Zamarin D; Lesokhin AM
    Curr Opin Oncol; 2014 Nov; 26(6):600-7. PubMed ID: 25250678
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Targeted molecular therapy and immunotherapy for prostate cancer].
    Grüllich C; Nößner E; Pfister D; Grünwald V
    Urologe A; 2020 Jun; 59(6):687-694. PubMed ID: 32303774
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapy of hepatocellular carcinoma: strategies for combinatorial intervention.
    Tian M; Shi Y; Liu W; Fan J
    Sci China Life Sci; 2019 Sep; 62(9):1138-1143. PubMed ID: 31119560
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted Therapy and Immunotherapy for Lung Cancer.
    Naylor EC; Desani JK; Chung PK
    Surg Oncol Clin N Am; 2016 Jul; 25(3):601-9. PubMed ID: 27261918
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacogenomics: Biomarker-Directed Therapy for Bladder Cancer.
    Jones RT; Felsenstein KM; Theodorescu D
    Urol Clin North Am; 2016 Feb; 43(1):77-86. PubMed ID: 26614030
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapy in nonmuscle invasive bladder cancer: current and emerging treatments.
    Gupta M; Kates M; Bivalacqua TJ
    Curr Opin Oncol; 2019 May; 31(3):183-187. PubMed ID: 30893148
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted agents and immunotherapies: optimizing outcomes in melanoma.
    Luke JJ; Flaherty KT; Ribas A; Long GV
    Nat Rev Clin Oncol; 2017 Aug; 14(8):463-482. PubMed ID: 28374786
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systemic therapies in hepatocellular carcinoma: present and future.
    Bertino G; Di Carlo I; Ardiri A; Calvagno GS; Demma S; Malaguarnera G; Bertino N; Malaguarnera M; Toro A; Malaguarnera M
    Future Oncol; 2013 Oct; 9(10):1533-48. PubMed ID: 24106903
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combining immunotherapy with oncogene-targeted therapy: a new road for melanoma treatment.
    Aris M; Barrio MM
    Front Immunol; 2015; 6():46. PubMed ID: 25709607
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Personalized Oncology Meets Immunology: The Path toward Precision Immunotherapy.
    Mandal R; Chan TA
    Cancer Discov; 2016 Jul; 6(7):703-13. PubMed ID: 27107038
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-PD-1/PD-L1 Therapy for Non-Small-Cell Lung Cancer: Toward Personalized Medicine and Combination Strategies.
    Sui H; Ma N; Wang Y; Li H; Liu X; Su Y; Yang J
    J Immunol Res; 2018; 2018():6984948. PubMed ID: 30159341
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cancer immunotherapy: present status, future perspective, and a new paradigm of peptide immunotherapeutics.
    Miller MJ; Foy KC; Kaumaya PT
    Discov Med; 2013 Mar; 15(82):166-76. PubMed ID: 23545045
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical cancer advances 2011: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology.
    Vogelzang NJ; Benowitz SI; Adams S; Aghajanian C; Chang SM; Dreyer ZE; Janne PA; Ko AH; Masters GA; Odenike O; Patel JD; Roth BJ; Samlowski WE; Seidman AD; Tap WD; Temel JS; Von Roenn JH; Kris MG
    J Clin Oncol; 2012 Jan; 30(1):88-109. PubMed ID: 22147736
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The between Now and Then of Lung Cancer Chemotherapy and Immunotherapy.
    Visconti R; Morra F; Guggino G; Celetti A
    Int J Mol Sci; 2017 Jun; 18(7):. PubMed ID: 28653990
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.